| Psoriasis vulgaris
Zoryve Cream vs Lexette
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Zoryve vs Lexette with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLexette has a higher rate of injection site reactions vs Zoryve based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lexette but not Zoryve, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoryve
Lexette
At A Glance
Topical
Daily
PDE4 inhibitor
Topical
Twice daily
Corticosteroid
Indications
- Psoriasis vulgaris
- Dermatitis, Atopic
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Psoriasis vulgaris Apply a thin uniform film to affected skin twice daily for up to 2 weeks; shake can and invert before use; do not exceed 50 g per week; avoid face, groin, and axillae; not for use with occlusive dressings unless directed by physician.
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
—
Adverse Reactions
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Most common (>=1%) Application site burning/stinging, application site pain, headache
Postmarketing Folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, miliaria
Pharmacology
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Topical super-high potency corticosteroid; halobetasol propionate plays a role in cellular signaling, immune function, inflammation, and protein regulation, though its precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Lexette
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Lexette
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Lexette
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Lexette.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoryveView full Zoryve profile
LexetteView full Lexette profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.